Announcements Trials

Browse Landscape

Phase

Phase 2 1 Phase 1 1

Status

Withdrawn 1 Completed 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Malignant mesenchymal tumor 1 Carcinoma 1

Interventions

Paclitaxel 291 Gemcitabine 254 Carboplatin 253 Cisplatin 250 Radiotherapy 219 Cyclophosphamide 218 Irinotecan 184 pembrolizumab 180 Docetaxel 174 Bevacizumab 166 Capecitabine 148 Nivolumab 141 Fluorouracil 132 Dexamethasone 125 Bortezomib 123 Oxaliplatin 115 Cytarabine 113 Erlotinib Hydrochloride 112 Temozolomide 110 Sorafenib 110 Doxorubicin 106 Rituximab 105 Leucovorin 105 Etoposide 105 Filgrastim 99 Everolimus 97 Lenalidomide 95 Ipilimumab 90 Pemetrexed 89 fludarabine phosphate 84

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1 × Completed × NHS-IL12 immunocytokine × Clear all

NCT01417546 2021-10-18

NHS-IL12 for Solid Tumors

National Institutes of Health Clinical Center (CC)

Phase 1 Completed

Malignant mesenchymal tumor, Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡